PrevEp is a Bethesda biotechnology company founded in 2018 by epilepsy researchers whose discoveries include Keppra and ezogabine. Its seven co-founders bring more than 150 years of combined experience to developing treatments for people with difficult unmet needs in epilepsy, including an intravenous topiramate program for neonatal seizures.
FDA Orphan Drug Designation
Compliance program
Orphan Drug Designation in the United States and Europe
Compliance program
505(b)(2) Regulatory Pathway
Compliance program
PatternGeeksPatternGeeks is developing a brain-machine interface for people with epilepsy: an EEG-based neurological monitoring device that uses artificial intelligence to predict and detect seizures. Founded by CEO Marsha Meytlis and CTO Maksim Kalashnikov, the company brings a focused startup team to a difficult clinical problem.
Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA
EVAX IncEVAX Inc. is the manufacturing and commercialization subsidiary of Enepret Incorporated, a company founded in 2017 to commercialize triterpene-production technologies developed at the University of Kentucky. Its lean team brings together synthetic-biology researchers and pharmaceutical manufacturing specialists to help vaccine developers move from early research into clinical work with non-animal adjuvants and their key ingredients. EVAX manufactures these materials in a 3,500-square-foot facility at the West Virginia University Innovation Corporation in Morgantown.MORGANTOWN, WV
Nuvation BioFounded in 2018 by biopharma veteran David Hung, M.D., Nuvation Bio develops and commercializes oncology medicines for difficult-to-treat cancers. The company’s portfolio includes the FDA-approved therapy IBTROZI® (taletrectinib) and investigational treatments supported by global clinical programs, with offices in the United States and China.New York, NY